Reviewing the regulatory barriers for nanomedicine: Global questions and challenges

Nanomedicine

Volumn 10, Issue 21, 2015, Pages 3275-3286

  Bowman, Diana M ^a   Gatof, Jake ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN LAW SCHOOL   (United States)

Author keywords

EU; global challenges; governance; health and safety; innovation; intellectual property; nanomaterials; regulation; USA

Indexed keywords

NANOMATERIAL;

HUMAN; MEDICAL TECHNOLOGY; NANOMEDICINE; PATENT; PRIORITY JOURNAL; REVIEW; INTERNATIONAL COOPERATION;

INTERNATIONALITY; NANOMEDICINE;

EID: 84944939648     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.169     Document Type: Review

References (64)

1. Fleming A. The discovery of penicillin. Br. Med. Bull. 2(1) 4-5 (1944).
2. Drews J. Drug discovery: a historical perspective. Science 287(5460), 1960-1964 (2000).
3. Croft S, Coombs G. Leishmaniasis-current chemotherapy and recent advances in the search for novel drugs. Trends Parasitol. 19(11), 502-508 (2003).
4. Rees J. Complex disease and the new clinical sciences. Science 296(5568), 698-700 (2002).
5. Collins F. The Language of Life: DNA and the Revolution in Personalized Medicine. Profile Books, NY, USA (2010).
6. Schweitzer S. Pharmaceutical Economics Policy. Oxford University Press, Oxford, UK (2006).
7. Friends of the Earth. Nanomaterials, Sunscreens and Cosmetics: Small Ingredients, Big Risks. Friends of the Earth, Melbourne, Australia (2006).
8. Chaudhry Q, Scotter M, Blackburn J et al. Applications and implications of nanotechnologies for the food sector. Food Add. Contam. 25(3), 241-258 (2008).
9. Chaudhry Q. Nanotechnology for food applications: current status and consumer safety concerns. Presented at: AAAS Annual Meeting. IL, USA, 16 February 2009.
10. Bowman DM, Calster GV, Friedrichs S. Nanomaterials and regulation of cosmetics. Nat. Nanotechnol. 5(2), 92 (2010).
11. Lenzer J. FDA is incapable of protecting us against anotherVioxx. BMJ 329(7477), 1253 (2004).
12. Horton R. Vioxx, the implosion of merck, and aftershocks at the FDA. Lancet 364(9450), 1995-1996 (2004).
13. Horton R. Offline: a serious regulatory failure, with urgent implications. Lancet 379(9811), 106 (2012).
14. European Science Foundation. ESF Forward Look on Nanomedicine. ESF, Brussels, Belgium (2005).
15. European Medicines Agency. Reflection Paper on Nanotechnology-Based Medicinal Froducts for Human Use. EMA, Brussels, Belgium (2006).
16. European Technology Platform. Nanomedicine: Nanotechnology for Health. European Commission, Brussels Belgium (2006).
17. Wagner V, Dullaart A, Bock AK, Zweck A. The emerging nanomedicine landscape. Nat. Biotechnol. 24(10), 1211-1217 (2006).
18. Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv. Drug Deliv. Rev. 58(14), 1456-1459 (2006).
19. Riehemann K, Schneider SW, Luger TA, Godin B., Ferrari M, Fuchs H. Nanomedicine-challenge and perspectives. Angew. Chem. Int. Ed. Engl. 48(5), 872-897 (2009).
20. Barenholz Y. Doxil-The first FDA-approved nano-drug: lessons learned. J. Control. Release 160(2), 117-134 (2012).
21. Etheridge M, Campbell S, Erdman A, Haynes C, Wolf S Mccullough J. The big picture of nanomedicine: the state of investigational and approved nanomedicine products. Nanomedicine 9(1), 1-14 (2013).
22. Tinkle S, McNeil SE, Mühlebach S et al. Nanomedicines: addressing the scientific and regulatory gap. Ann. NY Acad. Sci. 1313(1), 35-56 (2014).
23. NanoFUSE® DBM. www.nanotherapeutics.com/nanofuse-dbm2/
24. Royal Society and Royal Academy of Engineers. Nanoscience and nanotechnologies: opportunities and uncertainties (2004).
25. HM Government. Response to the royal society and royal academy of engineering report: 'nanoscience and nanotechnologies: opportunities and uncertainties' (2005).
26. Ludlow K, Bowman DM, Hodge GA. Review of possible impacts of nanotechnology on Australia's regulatory framework (2007).
27. Bowman DM, Hodge GA. A small matter of regulation: an international review of nanotechnology regulation. Columbia Sci. Technol. Law Rev. 8(1), (2007).
28. MHRA. How we regulate nanotechnology. (March 9, 2014).
29. Committee on Human Medicines. The toxicology of nanoparticles used in healthcare products (2006).
30. European Medicines Agency. Reflection paper on nanotechnology-based medicinal products for human use (2006).
31. FDA Nanotechnology Task Force. Nanotechnology: a report of the (US) Food and Drug Administration (2007).
32. Taylor MR. Regulating the products of nanotechnology: Does the FDA have the tools it needs (2006).
33. Centre for Food Safety and Applied Nutrition. Guidance for industry: safety of nanomaterials in cosmetic products-draft guidance (2012).
34. Centre for Food Safety and Applied Nutrition. Guidance for industry: assessing the effects of significant manufacturing process changes, including emerging technologies, on the safety and regulatory status of food ingredients and food contact substances, including food ingredients that are colour additives-draft guidance. (2012).
35. Faunce T, Murray K, Nasu H, Bowman D. Sunscreen safety: the precautionary principle, the australian therapeutic goods administration and nanoparticles in sunscreens. Nanoethics 2(3), 231-240 (2008).
36. Therapeutic GoodsAdmnistration. Safety of sunscreens containing nanoparticles of zinc oxide or titanium dioxide. Department Health Ageing (2006).
37. Therapeutic GoodsAdmnistration. Literature review on the safety of titanium dioxide and zinc oxide on nanoparticles in sunscreens. Department Health Ageing (2013).
38. European Commission. Accompanying document to the communication from the commission to the parliament, the council and the european economic and social committeeregulatory aspects of nanomaterials. In-depth review of the effectiviness of the EU's regulatory regimes for addressing nanotechnologies (2008).
39. European Commission. Communication on regulation aspects of nanomaterials. European Commission, Brussels Belgium (2008).
40. European Commission. Second regulatory review on nanomaterials. European Commission, Brussels, Belgium (2012).
41. European Medicines Agency. Non-clinical studies for generic nanoparticle iron medicinal products applications (2011).
42. European Medicines Agency. Data requirements for intravenous liposomal products developed with reference to an innovator liposomal product (2013).
43. European Medicines Agency. Surface coatings: general issues for consideration regarding parental administration of coated nanomedicine products (2013).
44. European Medicines Agency. Data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product (2013).
45. European Medicines Agency. Development of blockcopoloymer-micelle medicinal products (2014).
46. Ehmann F, Sakai-Kato K, Duncan R et al. Nextgeneration nanomedicines and nanosimilars: Eu regulators' initiatives relating to the development and evaluation of nanomedicines. Nanomedicine 8(5), 849-856 (2013).
47. Bind Therapeutics. http://bindtherapeutics.com/technology/accurins.html
48. Kalarx. http://kalarx.com/about-us/overview/
49. Linkov I, Satterstrom K, Corey L. Nanotoxicology and nanomedicine: making hard decisions. Nanomedicine 4 167-171 (2008).
50. Fadel TF, Steevens JA, Thomas TA, Linkov I. Managing nanotechnology risk management. Nano Today (2015) (Epub ahead of print).
51. Oberdörster G. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J. Intern. Med. 267, 89-105 (2009).
52. Nanomarkets. The impact of nanotechnology in drug delivery: global developments, market analysis and future prospects. Market Res. Reports Nanomarkets. www.pharmamanufacturing.com/whitepapers/2007/044/
53. Miller J. Beyond biotechnology: FDA regulation of nanomedicine. Columbia Sci. Technol. Law Rev. IV, (2003).
54. Jain K, Kesharwani P, Gupta U, Jain NK. Dendrimer toxicity: let's meet the challenge. Int. J. Pharmaceut. 394(1) 122-142 (2010).
55. Nijihara R, Balakrishnan K. Bringing nanomedicines to market: regulatory challenges, opportunities, and uncertainties. Nanomedicine 2, 127-136 (2006).
56. Mehta MD. The future of nanomedicine looks promising but only if we learn from the past. Health Law Rev. 13(1) 16-18 (2004).
57. Cormick C. Why do we need to know what the public thinks about nanotechnology Nano Ethics 3(2), 167-173 (2009).
58. Gupta N, Fischer ARH, Frewer LJ. Ethics, risk and benefits associated with different applications of nanotechnology: a comparison of expert and consumer perceptions of drivers of societal acceptance. Nano Ethics 9(2), 1-16 (2015).
59. Gaspar RS. Therapeutic products: regulating drugs and medical devices. In: International Handbook on Regulating Nanotechnologies. Edward Elgar, Cheltenham, UK, 291-320 (2010).
60. Ohno Y. Ich guidelines-implementation of the 3Rs (refinement, reduction, and replacement): incorporating best scientific practices into the regulatory process. ILAR J. 43(Suppl. 1), S95-S98 (2002).
61. Branch SK. Guidelines from the international conference on harmonisation (ich). J. Pharmaceut. Biomed. Anal. 38(5) 798-805 (2005).
62. OECD. Six years of OECD work on the safety of manufactured nanomaterials: achievements and future opportunities (2012).
63. Sylvester D, Bowman DM. Navigating the patent landscapes for nanotechnology: English gardens or tangled grounds Methods Mol. Biol. 726, 359-78 (2011).
64. Bawa R, Bawa SR, Maebius S, Flynn T, Wei C. Protecting new ideas and inventions in nanomedicine with patents. Nanomedicine 1, 150-158 (2005).